Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray

被引：124
作者：
He, Jiehua [2 ,3 ]
Peng, Roujun [1 ,2 ]
Yuan, Zhongyu [1 ,2 ]
Wang, Shusen [1 ,2 ]
Peng, Jiewen [4 ]
Lin, Guinan [4 ]
Jiang, Xiaomei [4 ]
Qin, Tao [1 ,2 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
[2] State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
[4] Zhongshan City Pepoles Hosp, Dept Med Oncol, Zhongshan 528403, Peoples R China
来源：
MEDICAL ONCOLOGY | 2012年 / 29卷 / 02期
关键词：
Breast carcinoma; Triple-negative; Androgen receptor; Prognosis; Tissue microarrays; CLINICAL-OUTCOMES; BRAIN METASTASES; RECURRENCE; SUBTYPES; RISK;
D O I：
10.1007/s12032-011-9832-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of this study is to analyze the prognostic value of androgen receptor (AR) expression for patients with triple-negative breast cancer (TNBC). Clinical data of these patients were collected and analyzed, and immunohistochemical staining for AR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from January 1995 to December 2008. AR expression was found in 25.8% of the cases with TNBC. TNBC patients with AR negative have a higher proportion of positive lymph node. A significant correlation was found between AR expression and disease-free survival (DFS) and overall survival (OS). Univariated analysis indicated that AR expression had a significant prognostic value in TNBC patients, whereas multivariate analysis indicated that AR was a significant independent prognostic factor of DFS (P = 0.032) in all patients. Our results suggested that AR was a favorable prognostic factor of DFS and OS in patients with TNBC. Therefore, TNBC may be further divided into two subtypes according to AR status.
引用
收藏
页码：406 / 410
页数：5
相关论文
共 15 条
[1]   Androgen receptor expression in estrogen receptor-negative breast cancer - Immunohistochemical, clinical, and prognostic associations [J].
Agoff, SN ;
Swanson, PE ;
Linden, H ;
Hawes, SE ;
Lawton, TJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (05) :725-731
[2]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[3]  
Brys M, 2000, Med Sci Monit, V6, P433
[4]   The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].
Carey, Lisa A. ;
Dees, E. Claire ;
Sawyer, Lynda ;
Gatti, Lisa ;
Moore, Dominic T. ;
Collichio, Frances ;
Ollila, David W. ;
Sartor, Carolyn I. ;
Graham, Mark L. ;
Perou, Charles M. .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334
[5]   Triple-negative breast cancer: Clinical features and patterns of recurrence [J].
Dent, Rebecca ;
Trudeau, Maureen ;
Pritchard, Kathleen I. ;
Hanna, Wedad M. ;
Kahn, Harriet K. ;
Sawka, Carol A. ;
Lickley, Lavina A. ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434
[6]   An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen [J].
Doane, A. S. ;
Danso, M. ;
Lal, P. ;
Donaton, M. ;
Zhang, L. ;
Hudis, C. ;
Gerald, W. L. .
ONCOGENE, 2006, 25 (28) :3994-4008
[7]   Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer [J].
Gonzalez-Angulo, Ana M. ;
Stemke-Hale, Katherine ;
Palla, Shana L. ;
Carey, Mark ;
Agarwal, Roshan ;
Meric-Berstam, Funda ;
Traina, Tiffany A. ;
Hudis, Clifford ;
Hortobagyi, Gabriel N. ;
Gerald, William L. ;
Mills, Gordon B. ;
Hennessy, Bryan T. .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2472-2478
[8]   Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women [J].
Hankinson, SE ;
Willett, WC ;
Manson, JE ;
Colditz, GA ;
Hunter, DJ ;
Spiegelman, D ;
Barbieri, RL ;
Speizer, FE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (17) :1292-1299
[9]   Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer [J].
Hines, S. L. ;
Vallow, L. A. ;
Tan, W. W. ;
McNeil, R. B. ;
Perez, E. A. ;
Jain, A. .
ANNALS OF ONCOLOGY, 2008, 19 (09) :1561-1565
[10]   Tissue microarrays for high-throughput molecular profiling of tumor specimens [J].
Kononen, J ;
Bubendorf, L ;
Kallioniemi, A ;
Bärlund, M ;
Schraml, P ;
Leighton, S ;
Torhorst, J ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
NATURE MEDICINE, 1998, 4 (07) :844-847
12